 |
|
All Releases
 |
OXiGENE to Present at BIO CEO & Investor Conference
Feb 6, 2012
|
10.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb. 6, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that Peter Langecker, MD, PhD, President and Chief Executive Officer, will present a corporate overview and business update at the BIO C...
|
|
OXiGENE and Azanta A/S Establish Partnership to Provide ZYBRESTAT(TM) for ATC in Europe on Named Patient, Compassionate Use Basis
Dec 12, 2011
|
20.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., and HELLERUP, Denmark, Dec. 12, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, and Azanta Danmark A/S, a specialty pharmaceutical company focused on oncology, women's health and addiction medicine, have esta...
|
|
OXiGENE Presents Data From FAVOR Study of ZYBRESTAT in PCV
Dec 7, 2011
|
13.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that Dr. Timothy Lai, MD, FRCS, FRCOphth, Honorary Clinical Associate Professor of Ophthalmology from the Chinese University of Hong Kon...
|
|
OXiGENE Announces Purchase Agreement for Up to $20 Million With Lincoln Park Capital
Nov 28, 2011
|
14.0 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 28, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has signed a purchase agreement for the sale, from time to time, of up to $20 million of its common stock with Lincoln Park Cap...
|
|
OXiGENE Reports Third Quarter 2011 Financial Results
Nov 9, 2011
|
21.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 9, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and nine months ending September 30, 2011 and provided an update on recent clinical and corporate progress.
...
|
|
OXiGENE Reports Final Data From Phase 2 FALCON Study of ZYBRESTAT in Non-Small Cell Lung Cancer
Nov 3, 2011
|
16.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 3, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced final results today from the FALCON trial, a stratified, randomized, controlled Phase 2 study of ZYBRESTAT™ (fosbretabulin tromethamine,...
|
|
OXiGENE Announces Third Quarter 2011 Earnings Conference Call and Webcast
Nov 2, 2011
|
12.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report third quarter 2011 results on Wednesday, November 9, 2011. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ...
|
|
OXiGENE Presents Data Confirming Survival Benefit of ZYBRESTAT in Patients With Anaplastic Thyroid Cancer
Sep 14, 2011
|
17.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today presented data from a retrospective comparative analysis suggesting that treatment with ZYBRESTAT (fosbretabulin, or CA4P) confers a one-year su...
|
|
OXiGENE Announces Changes to Board of Directors
Sep 9, 2011
|
14.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Sept. 9, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced changes to the Board of Directors, including the appointment of Gerald McMahon, Ph.D. and the impending retirement of William Shiebler ...
|
|
OXiGENE to Present Additional ZYBRESTAT(TM) Survival Data at European Thyroid Association Annual Meeting
Sep 7, 2011
|
14.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Sept. 7, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will present data suggesting improved one-year survival with ZYBRESTAT compared to historical survival rates in patients with anaplastic thyroid cance...
|
|
OXiGENE Announces Restructuring to Focus Resources on Promising Earlier Stage Clinical Programs
Sep 1, 2011
|
17.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Sept. 1, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today a restructuring plan designed to focus the Company's capital resources on its most promising early-stage clinical programs and further...
|
|
OXiGENE Reports Second Quarter 2011 Financial Results
Aug 10, 2011
|
25.0 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ending June 30, 2011 and provided an update on recent clinical and corporate progress.
Financial Re...
|
|
OXiGENE Reports Second Quarter 2011 Financial Results
Aug 3, 2011
|
12.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Aug. 3, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report second quarter 2011 results on Wednesday, August 10, 2011. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm...
|
|
ZYBRESTAT(TM) Results Suggest Improvement in Overall Survival in Phase 2/3 Study in Anaplastic Thyroid Cancer
Jun 6, 2011
|
18.6 KB |
|
| |
Median Overall Survival Extended by 1.2 Months for ZYBRESTAT Patients
One-Year Survival Almost Tripled With ZYBRESTAT Plus
Chemotherapy Compared to Chemotherapy Alone (26% vs. 9%)
ZYBRESTAT Oral Presentation Included in "Best of ASCO®"
SOUTH SAN FRANCISCO, Calif., June 6, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (N...
|
|
OXiGENE Complies With NASDAQ Listing Requirements
Jun 6, 2011
|
12.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., June 6, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced the Company has regained compliance with the minimum Market Value of Listed Securities (MVLS) requirement for continued listing on The ...
|
|
OXiGENE Reports Encouraging Data From Phase 2 Trial of ZYBRESTAT(TM) in Non-small Cell Lung Cancer
Jun 4, 2011
|
18.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., June 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a stratified randomized, controlled Phase 2 study of...
|
|
OXiGENE Announces Clinical Data From FACT and FALCON Studies to be Presented at ASCO
May 18, 2011
|
15.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 18, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from its clinical trials of ZYBRESTAT™ in combination with chemotherapy in patients with anaplastic thyroid cancer (ATC...
|
|
OXiGENE Reports First Quarter 2011 Financial Results
May 12, 2011
|
22.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 12, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ending March 31, 2011 and provided an update on recent clinical and corporate progress.
Financial Re...
|
|
OXiGENE Announces Initiation of Phase 1 Trial of OXi4503 in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
May 12, 2011
|
19.2 KB |
|
| |
OXi4503 is a Novel, Dual-Action Vascular Disrupting Agent
The Leukemia & Lymphoma Society to Provide Study Support
SOUTH SAN FRANCISCO, Calif., May 12, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today tha...
|
|
OXiGENE Announces First Quarter 2011 Earnings Conference Call and Webcast
May 6, 2011
|
12.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 6, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report first quarter 2011 results on Thursday, May 12, 2011. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm EDT (...
|
|
|
= add release to Briefcase |
|
 |
|
10:45 AM ET - 02/08/12 |
|
$1.25
( 0.00)
|
Volume | 425,200 |
Day High | 1.34 |
Day Low | 1.25 |
52-week High | 6.38 |
52-week Low | 0.82 |
» more |
|
|
|
|
 |
|
 |
|
Shareholder Briefcase
Download Library
RSS News Feeds
| |
|
|
|
|
